About Us

About Us

About Us

Blueprint Medicines is a patient-driven oncology company developing highly selective kinase inhibitors for genomically defined cancer subsets. Led by a management team and advisors with world-renowned expertise in cancer genomics, drug discovery and clinical oncology, Blueprint has developed a platform that combines genomics with a novel library of kinase inhibitors, enabling Blueprint to rapidly develop potent highly selective compounds against clear genomic driver targets.

By focusing on highly selective drugs for genomically defined cancer patients, Blueprint has the potential with each of its personalized, precision medicine programs to demonstrate clear value creation early in the clinic, which could dramatically reduce the time and cost necessary to bring a new drug to market. The company expects to bring two to three programs to the clinic by the end of 2015.

Developing Highly Selective Kinase Drugs For Specific Genomically-Defined Cancer Patients